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Abstract
Background
Hidradenitis Suppurativa (HS) is a painful, chronic inflammatory skin disease. Global esti-
mates of prevalence vary between 0.03% and 4% of the population.
Our main aim was to determine HS prevalence in the Australian adult population focus-
sing on the demographics, management pathways and diagnosis rate of individuals living
with HS.
Methods
In this population-based cross-sectional study, 17,050 individuals representative of the Aus-
tralian adult population were asked through face-to-face household interviews to answer a
previously validated HS screening questionnaire with high diagnostic power. Individuals
who screened positive were asked additional questions, including previous diagnosis of HS
and number/type of physicians consulted regarding their condition.
Results
11,433 Australian residents answered the HS questionnaire, 88 screening positive for HS
(0.77%; 95% CI 0.62–0.95). Considering the previously reported sensitivity (0.97) and positive
predictive value (0.85) of the screening questionnaire, HS prevalence was estimated to be
0.67% (95% CI 0.53%-0.84%). 6 of 88 suspected HS individuals reported a pre-existing HS
diagnosis (6.8%; 95% CI 3.2%-14.1%). 25.6% of the undiagnosed individuals suspected of
having HS had not seen any clinicians regarding their boils; the remaining ones had consulted
General Practitioners (96.7%), and clinicians from different specialties. Comparisons of indi-
viduals who screened positive for HS versus those who screened negative demonstrated
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Data Availability Statement: Anonymized, patient-
level data are available upon request. Qualified
researchers engaged in rigorous, independent
scientific research can request access to the
anonymized data sets from the following website
https://www.abbvie.com/our-science/clinical-trials/
clinical-trials-data-and-information-sharing/data-
and-information-sharing-with-qualified-
researchers.html. AbbVie’s responsible data
sharing methodology includes the implementation
of measures to protect the privacy of clinical trial
participants, and staff members associated with
statistically significant differences in gender (p = 0.0046), age (p<0.0001), BMI (p = 0.0307),
smoking status (p<0.0001), employment status (p<0.0001) and income (p = 0.0321).
Conclusions
The prevalence of HS in Australia was estimated to be 0.67% (95% CI 0.53%-0.84%). The
diagnosis rate amongst the suspected HS cases was low, which appeared to be due to a
combination of patients not seeking help and decentralization of care. Individuals suspected
of having HS were more likely to be females, young, obese, smokers, unemployed or at
home duties and having lower annual personal income in comparison with individuals not
suspected of having HS.
Introduction
Hidradenitis Suppurativa (HS) (also known in the past as acne inversa) is a chronic, progres-
sive, inflammatory and relapsing skin disease with a severe negative impact on Quality of Life
(QoL) and often associated with low socioeconomic status [1, 2]. It is characterized by painful
inflammatory lesions mainly located in the inverse body areas, most commonly the axillae,
groin, buttocks, and inframammary areas [3]. The lesions consist of nodules which can prog-
ress to abscesses, sinus tracts (tunnels) and scarring [4].
The disease causes obvious morbidity and its severity is usually classified using the Hurley
staging according to the most severely affected region [5]:
• Stage I (Mild)—Abscess formation, single or multiple, without sinus tracts and cicatrization
• Stage II (Moderate)—Recurrent abscesses with tract formation and cicatrization, single or
multiple, and widely separated lesions
• Stage III (Severe)—Diffuse or near-diffuse involvement or multiple interconnected tracts
and abscesses across the entire area
Currently, HS is often managed and/or diagnosed by many different specialties, such as sur-
geons, emergency physicians, plastic surgeons, infectious disease specialists, general practition-
ers, and dermatologists [6]. Nevertheless, the mean time between symptom onset and HS
diagnosis has been reported to be 7.2 years in a wide range of countries [7], and HS patients
are reportedly often misdiagnosed or undiagnosed [8]. This may indicate that not all clinicians
are familiar with the disease and/or that many patients do not consistently seek medical help
[1]. Because of the severe impact that HS has on patients, it is particularly important to under-
stand prevalence and diagnosis rates of HS, as well as the profile and characteristics of people
living with HS and their management pathways. This knowledge could assist in developing
strategies to inform physicians and patients of the disease and identify patients affected by it,
with the ultimate aspiration of preventing progression, disfigurement, pain, and disability.
Several studies have attempted to determine HS prevalence in different settings and using
different methods. The result is a set of highly variable estimations of HS prevalence, ranging
between 0.03% and 4% of the population [6, 9–11]. Three types of studies have been pursued
so far: (I) registry-based studies, (II) prospective examination of patients, and (III) self-
reported data from larger groups (e.g. population-based studies) [6]. These different designs
each have their strengths and weaknesses. However, the most reliable prevalence estimates
come from cross-sectional, general population-based studies using validated screening
HS in Australia: Prevalence, demographics and management pathways
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questions and/or clinical assessment. Patients most often describe the disease as ‘‘boils” [12],
and it has been proposed that the clear symptomatology (painful lesions recognized by patients
as boils), the specific areas affected, and the recurrence/chronicity of the lesions are sufficient
for reliable, self-reported diagnosis [13, 14]. Three different questionnaires based on those cri-
teria have been tested and validated by Esmann and colleagues [13] and shown to have high
diagnostic power to identify individuals affected by HS and can therefore be used as a tool for
population-based epidemiology studies of HS.
There is also uncertainty around the estimations of HS severity distribution. Hurley stage I
and II disease have been reported to be the most common among diagnosed HS individuals,
affecting between 24–68% and 28%-54% of HS patients respectively, depending on the study
[10, 15–19]. Stage III is less common, occurring in 2–29% of HS patients [10, 15–19]. These
studies are however subject to selection bias as they mainly reflect the severity distribution
among HS patients under care and therefore have not taken into account the undiagnosed
pool of HS patients. The development and validation of a self-administered questionnaire able
to predict the severity of HS would offer advantages over physical assessment in population-
based epidemiologic research and allow for the estimation of HS severity distribution amongst
the wider HS population.
Here we aimed to determine HS prevalence in the Australian adult population through a
population-based cross-sectional study using a previously validated HS screening questionnaire
with high diagnostic power [13]. HS diagnosis rate as well as demographics, profile and man-
agement pathways of individuals living with HS were also assessed. In parallel, with the aim of
enabling the estimation of HS severity distribution in our study population, we also performed
a cross-sectional observational study to assess the ability of a newly developed self-administered
HS severity questionnaire to predict HS severity as defined by the Hurley staging system.
Methods
The project reported here consisted of two separate studies: (I) A cross-sectional observational
study to assess the ability of an experimental, newly developed, self-reported HS severity ques-
tionnaire to predict Hurley Stage in HS patients; and (II) a multi-stage cross-sectional observa-
tional study to determine the prevalence of HS in the Australian population.
Design
Validation of an experimental self-administered questionnaire to predict the severity of
HS: A cross-sectional observational study. An experimental self-administered HS severity
questionnaire (Table 1) was developed by the authors based on physical and social characteris-
tics of HS that were believed to be able to distinguish between the 3 Hurley stages of the dis-
ease. A broad spectrum of questions were devised covering all anticipated disease features that
could be readily reported by patients with the objective of narrowing the list of questions post-
study. A total of 117 consecutive patients presenting to 10 Australian dermatology clinics with
a diagnosis of HS and age of 18 or older were enrolled in this study. Approximately one-third
of HS patients were recruited for each Hurley stage (N = 39 Stage I, N = 43 Stage II, and
N = 35 Stage III). During a single study visit, the study subjects completed both an experimen-
tal, newly developed self-administered HS severity questionnaire (Table 1) and DLQI (Derma-
tology Life Quality Index), and underwent a physical assessment by their treating
dermatologist for assessing the severity of the disease based on Hurley staging. Demographics
and medical history were also collected for each patient: concomitant medical conditions,
duration of HS symptoms, time since diagnosis and medications used to treat HS were
recorded in a short form.
HS in Australia: Prevalence, demographics and management pathways
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HS Epidemiology in Australia: A population-based cross-sectional observational
study. This study consisted of two stages: Stage 1—Survey of the adult general population;
Stage 2 –Clinical assessment and Expert Review (Fig 1).
In Stage 1 of the epidemiology study, all adult ( 18yo) Australian residents participating
in the Single Source establishment survey run by Roy Morgan Research Ltd [20] were eligible
to be included. The single source sample is representative of the Australian population aged 14
years and older in terms of gender, age and geographic location. The sample is constructed
using random sample and geographical stratification to cover all states and territories. In addi-
tion to the standard questions administered in the Roy Morgan Single Source Establishment
Survey, which include demographic characteristics, study specific questions were administered
to those who consented. The survey was conducted face-to-face, and a total of 17,050 individu-
als interviewed between the 1st of August 2015 and the 11th of December 2015 were asked for
consent to be administered the study questions. The survey provider Roy Morgan is governed
by professional standards set out in the Code of Professional Behaviour of the Australian Mar-
ket and Social Research Society and ethical standards as set out by Ethical Standard Opinions
and Marketing Research Professionals.
Consenting individuals firstly responded to the HS screening questionnaire previously vali-
dated by Esmann et al (“Do you repeatedly have outbreaks of big sore or painful nodules or
boils that heal with scars in any of these locations: Groin, Armpits, Sexual organs, Anal region,
Under the breasts, Folds on the Stomach/around the navel”), which has high sensitivity and
positive predictive value (SE 0.97; PPV 0.85) [13]. As shown in S1 Table (Supporting
Table 1. Experimental HS severity questionnaire.
1. In the last 6 months, how many sore or painful boils/lumps at least 1 cm (or half an inch) in diameter have you had?
a. 0 b. 1 c. 2–3 d. 4–6 e. >6
2. In the last 6 months, what is the most pain you have experienced from your boils or lumps (0 is no pain and 10 is unbearable pain)?
NO PAIN WORST PAIN I CAN IMAGINE
☐ 0 ☐ 1 ☐ 2 ☐ 3 ☐ 4 ☐ 5 ☐ 6 ☐ 7 ☐ 8 ☐ 9 ☐ 10
3. Have you ever had boils or lumps heal leaving scars that feel harder than the skin around the scars? (at any stage in your life, not just the last 6
months)
☐ Yes ☐No
4. In the last 6 months, have the boils or scars:
(tick Yes or No for each question)
a. Restricted your movements? ☐ Yes ☐No
b. Interfered with your work/school activities? ☐ Yes ☐No
c. Caused you embarrassment or shame? ☐ Yes ☐No
d. Impacted on personal or physical relationships? ☐ Yes ☐No
5. Does the skin of the area affected ever heal completely possibly leaving scars)?
☐ Yes ☐No
6. Does the area affected by the scarring ever feel “lumpy” or the contour of “bubble wrap”?
☐ Yes ☐No
7. How big is the area currently affected by scarring that you would regard as ugly/distressing?
a. Surface area of 3 hands or larger.
b. Surface area of less than 3 hands, but more than 2 hands.
c. Surface area of 2 hands or less.
[Note. You are being asked to use your hands as tools to measure the size of the affected area on other parts of your body. Place your hand (including
fingers) over the affected area to estimate the surface area, and repeat until the affected area/s have been covered.]
8. Does the area currently affected always contain some painful pus-filled boils, lumps and scars?
☐ Yes ☐No
https://doi.org/10.1371/journal.pone.0200683.t001
HS in Australia: Prevalence, demographics and management pathways
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Information), the questionnaire used in this study, as opposed to the original version from
Esmann and colleagues, also listed “Other locations”. However, in line with the validated ques-
tionnaire, a suspected HS subject had been defined as an individual with presence of outbreaks
AND at least one nodule/boil location other than “Other locations”. In our survey, the text was
also supplemented by a visual diagram showing the characteristic locations of boils/nodules
listed in the questionnaire in order to overcome any language barriers (S1 Table, Supporting
Information).
Individuals suspected of having HS based on the HS screening questionnaire, also com-
pleted the experimental HS severity questionnaire (Table 1) and were asked a different set of
additional study questions depending on whether they reported having been previously diag-
nosed with HS/acne inversa (S2 Table, Supporting Information). These questions included
number and type of physician(s) consulted regarding the condition of boils.
Fig 1. HS Epidemiology study flow chart.
https://doi.org/10.1371/journal.pone.0200683.g001
HS in Australia: Prevalence, demographics and management pathways
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In Stage 2 of the epidemiology study, all interviewed subjects who screened positive for the
HS screening questionnaire were invited to attend a visit with a dermatologist for clinical
assessment. Consenting subjects were contacted to schedule a visit at the closest dermatology
clinic among the 8 sites participating in the study (1 site in the Australian Capital Territory, 2
sites in the state of New South Wales, 1 site in the state of Queensland, 1 site in the state of
Western Australia, 2 sites in the state of Victoria, and 1 site in the state of South Australia).
Individuals attending the dermatology clinic underwent physical examination by a derma-
tologist between November 2015 and February 2016 to confirm HS diagnosis, assess the sever-
ity of the disease, and collect additional study-related information such as duration of
symptoms, presence of comorbidities, abscess and inflammatory nodule count (AN count),
past and current treatments for HS.
De-identified photographs of the lesions were uploaded onto a secure server for blinded
review by an international independent HS expert, with the goal of confirming both HS diag-
nosis and Hurley Staging.
Ethics and informed consents
HS severity questionnaire validation study. Ethics approval for the study was obtained
through the following HREC committees: Melbourne Health, Westmead Hospital, Bellberry
limited and St. Vincent’s Hospital Melbourne. Study participants received a unique study iden-
tification number, issued at the time informed written consent was obtained.
HS Epidemiology study. The study protocol, any amendments, the informed consents
and other information that required pre-approval were reviewed and approved by a central
ethics committee (Bellberry Limited). Informed consent of the participants was required.
Informed consent was obtained from the subjects (i) to administer the study-specific questions
during the household Roy Morgan survey in Stage 1 of the study (ii) where responses indicated
a possible HS diagnosis, to obtain contact details to schedule a visit at the closest dermatology
clinic (iii) at the dermatology clinic, prior to the clinical assessment. All consents were written
and signed by the study subjects except for the household survey, where subjects’ consent or
dissent to answer the HS questions was recorded by the Roy Morgan staff into a Computer
Assisted Personal Interviewing (CAPI) device, which was used to record the other answers to
the Roy Morgan survey questions. Only data from consenting subjects was received. Data col-
lected during the prevalence survey remained de-identified by the survey provider for partici-
pants screened as not having HS. Participants screening positive for HS and who agreed to
attend a clinical consult, were issued a unique participant identification number.
Outcome measures
HS severity questionnaire validation study. The study outcome measures were Hurley
Stage, DLQI and the completed experimental HS severity questionnaire. The DLQI and the
experimental HS severity questionnaire were self-administered; Hurley Stage was determined
via physical assessment.
HS Epidemiology study. The primary objective of the study was to calculate the crude HS
prevalence, estimated using the number of participants who screened positive for HS during
Stage 1 (Population Survey). The secondary objectives were to calculate the HS severity distri-
bution; and the combined prevalence of moderate and severe HS as determined by the experi-
mental HS severity questionnaire administered in Stage 1 subject to its validation. The
exploratory outcome measures were: number of participants diagnosed with HS during Stage
2 (Clinical Assessment & Expert Review); the HS severity distribution as determined by the cli-
nician in Stage 2; pathways to accessing clinical care; history of previous treatment; diagnosis
HS in Australia: Prevalence, demographics and management pathways
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rate among people living with HS; other health problems, duration of the condition and treat-
ments used, per severity level; number of participants diagnosed with HS during the expert
review of photographs; and the HS severity distribution as determined by the expert reviewer.
Statistical methods
HS severity questionnaire validation study. A sample size of 40 patients per stratum
(Hurley Stage I, II and III) was calculated to be able to estimate sensitivity/specificity parame-
ters with a precision ranging between 0.13 and 0.19 if the sensitivity and specificity parameters
were equal to 0.9. The sensitivity and specificity of the self-administered questionnaire and
DLQI to predict the severity of HS were assessed against the Hurley Stage.
The utility of each of the 8 questions included in the questionnaire was evaluated by fitting
each question in a univariate multinomial logistic regression model of Hurley Stage (mild,
moderate, or severe) and examining the association between each individual question and
Hurley Stage. The 8 questions were also included in a multivariate multinomial logistic regres-
sion model to determine if any significant associations in the univariate setting remained sig-
nificant after adjusting for the other questions. This approach was repeated using logistic
regression (for Hurley Stages “mild” versus “moderate or severe”; and “mild or moderate” ver-
sus “severe”).
After examining the association between the questions and Hurley Stage, the questionnaire
was used to predict Hurley Stage. The 8 questions of the questionnaire were included in a mul-
tivariate multinomial logistic regression model to give a predicted probability of the 3 Hurley
stages for each patient. The Hurley stage with the highest predicted probability was selected as
the predicted category for each patient. The predictive ability of the multinomial logistic
regression model to correctly classify the patients into the 3 Hurley stages (mild, moderate, or
severe) was assessed using the Kappa coefficient. The predictive ability of the model to classify
the patients into 2 Hurley stages (“mild” versus “moderate or severe”; and “mild or moderate”
versus “severe”) was assessed using sensitivity and specificity. This approach was repeated
using logistic regression (for 2 Hurley stages only) and discriminant analysis (for both 3 and 2
Hurley stages).
ROC curves were plotted for the multinomial logistic regression model, and logistic regres-
sion models to determine the predictive ability of the models at different decision thresholds.
For example, in considering 2 Hurley stages, a patient was classified into the category with the
highest predicted probability. This is equivalent to using a decision threshold of 0.5. The ROC
curves plot the results for 100 thresholds from 0.01 to 100.
The overall DLQI score was also used to predict Hurley stage, where patients with a total
DLQI score of 0–5 were predicted to be mild, 6–10 were predicted to be moderate, and 11–30
were predicted to be severe. This categorization was consistent with the results of the average
DLQI scores of HS patients in a previous Canadian study of 2.8 (SD = 2.4) for patients with
Hurley stage of mild, 8.3 (SD = 7.9) for patients with Hurley stage moderate, and 17.6
(SD = 8.0) for patients with Hurley Stage severe [21]. In a similar approach to the question-
naire, the ability of the DLQI to predict Hurley stage, was assessed using the Kappa coefficient.
The predictive ability of DLQI to classify the patients into 2 Hurley stages (“mild” versus
“moderate or severe”; and “mild or moderate” versus “severe”) was assessed using sensitivity
and specificity.
ROC curves were plotted to determine if the decision thresholds for DLQI score based on
the Canadian study were a reasonable approach, compared to using other decision thresholds.
HS Epidemiology study. Sample size calculation: Based on an anticipated prevalence of
1%, a sample size of 12,000 provided an exact 95% confidence interval with an absolute width
HS in Australia: Prevalence, demographics and management pathways
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of 0.36% (i.e. 0. 83% to 1.19%). For the distribution of severity, assuming a split of 40% vs 40%
vs 20% for mild, moderate and severe cases respectively, 95% confidence intervals were
expected to have a width comprised between 0.17% and 0.23%. Furthermore, 12,000 partici-
pants provided a 99% chance of getting at least 95 HS cases overall and at least 13 severe cases.
With an assumption of 10% severe cases, 12,000 participants provided a 99% chance of getting
at least 4 severe cases and a 90% probability of getting 8 or more severe cases.
The prevalence of HS was calculated as the number of subjects who screened positive for
suspected HS according to the screening questionnaire (S1 Table). These subjects reported
repeated outbreaks of big sore or painful nodules or boils that heal with scars in at least one of
these 6 locations: groin, armpits, sexual organs, anal region, under the breasts, folds on the
stomach /around the navel. A 95% confidence interval for the prevalence estimate was
obtained using the binomial Wilson method. Continuous variables were described for the
number of participants with valid observations and using mean, standard deviation (SD),
median, and quartiles, minimum and maximum. Categorical variables were described using
frequencies, denominators and percentage per class level. Socio-demographic characteristics
were compared between those with suspected HS and those without using chi-square tests for
categorical variables and t-tests for continuous variables. A post-hoc analysis comparing the
prevalence and boils locations between men and women was performed using a chi-square
test.
Results
I. Validation of an experimental self-administered questionnaire to predict
the severity of HS
The ability of an experimental HS severity questionnaire (Table 1) and DLQI to predict Hurley
Stage was assessed in a cross-sectional observational study enrolling 117 individuals affected
by HS attending dermatology clinics in Australia.
Patients’ characteristics. Approximately one-third of HS patients were recruited for each
Hurley stage. Patient demographics and DLQI scores by Hurley Stage are presented in Table 2.
The mean age of the study population was 39±14 years and two-thirds of patients (66.7%)
were female (Table 2).
Approximately half of the patients (53.8%) had experienced HS symptoms for 10 or more
years, however only 31.6% of patients had been diagnosed with HS for 10 or more years and
patients with more severe disease appeared to have had HS symptoms for a longer period of
time (Table 2). The mean DLQI score 11.8±8.1 (i.e. very large effect on quality of life) in the
overall population, mean scores by Hurley Stage are presented in Table 2.
Table 3 reports HS treatments received by the study patients in the past or at the time of the
study visit.
Almost all patients had been treated with oral antibiotics at some stage and independently
of the severity of their disease, and more than half of them had used topical treatments. Biolog-
ics, isotretinoin, and surgery treatments had mostly been used in Hurley Stage II and III
patients. Specifically 39.5% of Hurley stage II and 54.3% of Hurley stage III patients had
received surgery. Acitretin use was relatively low (8.5% overall) and had more commonly been
used to treat Stage III patients (17.1%) compared to Stage I (5.1%) or Stage II (4.7%) patients.
The most common past treatments for HS were oral antibiotics (48.7%), topical antibiotics
(41.9%), and surgery (35.9%) (S3 Table, Supporting Information). The most common current
treatments for HS were oral antibiotics (47%), topical antibiotics (23.1%) and oral contracep-
tive pills (16.2%) (S3 Table, Supporting Information).
HS in Australia: Prevalence, demographics and management pathways
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Impact of the disease on HS patients. Almost all enrolled patients (113/117) answered
every question of the HS severity questionnaire. Results are shown in the supporting informa-
tion (S4 Table, Supporting Information). The majority of patients (59.8%) had experienced at
least 4 sore or painful boils in the last 6 months (S4 Table, Question 1), and many (87.2%)
reported boils or lumps leaving scars harder than the skin around the scars, at some stage in
their lives (S4 Table, Question 3). Boils or scars in the last 6 months had often restricted the
patients’ movements (82.9%, S4 Table, Question 4a), interfered with their work/school activi-
ties (65.0%, S4 Table, Question 4b), caused embarrassment or shame (79.5%, S4 Table, Ques-
tion 4c), and impacted on personal or physical relationships (65.8%, S4 Table, Question 4d).
Table 2. Demographics, duration of the disease and DLQI scores by Hurley Stage of HS patients enrolled in the HS severity questionnaire validation study.
Hurley Stage
I (Mild)
(N = 39)
II (Moderate)
(N = 43)
III (Severe)
(N = 35)
All
(N = 117)
Age at enrollment
(Years)
Mean (SD) 36.7 (13.5) 39.6 (13.7) 42.3 (14.1) 39.4 (13.8)
Median 32.4 35.4 44.0 36.1
Min, Max 19.3, 68.7 19.6, 71.8 18.1, 70.5 18.1, 71.8
Gender Male 12 (30.8%) 14 (32.6%) 13 (37.1%) 39 (33.3%)
Female 27 (69.2%) 29 (67.4%) 22 (62.9%) 78 (66.7%)
Duration of HS Symptoms Less than 12 months 3 (7.7%) 2 (4.7%) 0 (0.0%) 5 (4.3%)
12 months to 5 years 15 (38.5%) 6 (14.0%) 4 (11.4%) 25 (21.4%)
5 to 10 years 9 (23.1%) 10 (23.3%) 5 (14.3%) 24 (20.5%)
10 years or longer 12 (30.8%) 25 (58.1%) 26 (74.3%) 63 (53.8%)
Length of HS Time since HS diagnosis Less than 12 months 14 (35.9%) 3 (7.0%) 4 (11.4%) 21 (17.9%)
12 months to 5 years 10 (25.6%) 19 (44.2%) 6 (17.1%) 35 (29.9%)
5 to 10 years 11 (28.2%) 6 (14.0%) 7 (20.0%) 24 (20.5%)
10 years or longer 4 (10.3%) 15 (34.9%) 18 (51.4%) 37 (31.6%)
Total DLQI scores Mean (SD) 10.3 (7.7) 10.5 (7.9) 15.0 (8.2) 11.8 (8.1)
Median 9.0 8.0 12.0 10.0
Min, Max 0.0, 28.0 0.0, 28.0 2.0, 30.0 0.0, 30.0
https://doi.org/10.1371/journal.pone.0200683.t002
Table 3. Combined past and current treatments for HS by Hurley Stage in patients enrolled in the HS severity questionnaire validation study.
Hurley Stage
I (Mild)
(N = 39)
II (Moderate)
(N = 43)
III (Severe)
(N = 35)
All
(N = 117)
Oral antibiotics 36 (92.3%) 42 (97.7%) 34 (97.1%) 112 (95.7%)
Topical antibiotics 20 (51.3%) 30 (69.8%) 26 (74.3%) 76 (65.0%)
Isotretinoin (oral medication) 10 (25.6%) 20 (46.5%) 23 (65.7%) 53 (45.3%)
Surgery 10 (25.6%) 17 (39.5%) 19 (54.3%) 46 (39.3%)
Oral contraceptive pill 11 (28.2%) 13 (30.2%) 12 (34.3%) 36 (30.8%)
Other oral medication or injection 10 (25.6%) 9 (20.9%) 11 (31.4%) 30 (25.6%)
Adalimumab 2 (5.1%) 11 (25.6%) 10 (28.6%) 23 (19.7%)
Clinical trial of a biologic 1 (2.6%) 10 (23.3%) 4 (11.4%) 15 (12.8%)
Acitretin (oral medication) 2 (5.1%) 2 (4.7%) 6 (17.1%) 10 (8.5%)
Infliximab 0 (0.0%) 3 (7.0%) 4 (11.4%) 7 (6.0%)
Etanercept 0 (0.0%) 1 (2.3%) 0 (0.0%) 1 (0.9%)
Ustekinumab 0 (0.0%) 0 (0.0%) 0 (0.0%) 0 (0.0%)
https://doi.org/10.1371/journal.pone.0200683.t003
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Approximately half of study patients (52.1%) rated their maximum pain as 8 out of 10 or
higher in the last 6 months. The mean pain score reported by the overall study population was
6.6±2.8 (S4 Table, Question 2).
The overall impact of HS on the study patients’ quality of life is confirmed by the DLQI
scores: for about half of patients (49.6%), HS had a very large or extremely large effect on their
quality of life (Table 4).
Ability of the HS severity questionnaire to predict Hurley Stage. The experimental HS
severity questionnaire included eight questions encompassing aspects such as the presence
and number of painful boils in the last 6 months, presence and size of scarring and impact of
boils and/or scars on pain, movements, daily activities, relationships, and embarrassment. The
full questionnaire is reported in Table 1.
Results from the multinomial logistic regression model showed that in the univariate analy-
ses, only two questions in the HS severity questionnaire had a statistically significant associa-
tion with Hurley Stage (p<0.05) (Table 5). Patients who answered “Yes” to “In the last 6
months, have the boils or scars interrupted your work/school activities?”, had a 3.5 times
greater odds of being Hurley Stage III than stage I (OR Stage III vs Stage I = 3.5, 95% CI 1.2–
10.3, p = 0.0247) (Question 4b, Table 5). In addition, patients with an area of “ugly/distressing”
scarred skin of greater than 2 hands had a 2.7 times greater odds of being Hurley Stage III than
Stage I (OR Stage III vs Stage I = 2.7, 95% CI 1.0–6.8, p = 0.0418) (Question 7, Table 5).
However, after adjusting for all the other questions in a multivariate analysis, only the asso-
ciation between Question 4b and Hurley Stage was still apparent (p = 0.0205). Patients who
answered “Yes” to “In the last 6 months, have the boils or scars interrupted your work/school
activities?” had a 5.8 times greater odds of being Hurley Stage III than Stage I (OR Stage III vs
Stage I = 5.8, 95% CI 1.3 to 25.3, p = 0.0205) (Table 5).
The results were similar using logistic regression to model “mild” versus “moderate” or
“severe”. In the univariate analyses, there was no statistically significant association between
any question and Hurley Stage and in the multivariate analysis there was no statistically signifi-
cant association between any question and Hurley Stage except for Question 4b, where
patients who answered “Yes” to Question 4b were 3.18 times more likely to be Hurley Stage
severe/moderate compared to mild (OR severe vs mild = 3.18, 95% CI 1.04 to 9.71, p-
value = 0.0427).
Similarly, using logistic regression to model “severe” versus “mild” or “moderate”, there
was no statistically significant association between any question and Hurley Stage, except for
Question 4b, where patients who answered “Yes” were 3.03 times more likely to be Hurley
Stage “severe” compared to “mild” or “moderate” (OR severe vs mild/moderate = 3.03, 95% CI
1.13 to 8.14, p-value = 0.0279). In the multivariate analysis the association between Question
4b and Hurley Stage was close to statistically significant (p-value = 0.0557), where patients
who answered “Yes” to Question 4b were 3.66 times more likely to be Hurley Stage “severe”
compared to “mild” or “moderate” (OR severe vs mild/moderate = 3.66, 95% CI 0.97 to 13.84).
Table 4. Impact of HS on quality of life in patients enrolled in the HS severity questionnaire validation study.
DLQI scores and associated meaning All enrolled population
(N = 117)
No effect at all on patient’s life (0–1) 7 (6.0%)
Small effect on patient’s life (2–5) 25 (21.4%)
Moderate effect on patient’s life (6–10) 27 (23.1%)
Very large effect on patient’s life (11–20) 33 (28.2%)
Extremely large effect on patient’s life (21–30) 25 (21.4%)
https://doi.org/10.1371/journal.pone.0200683.t004
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For the HS severity questionnaire, the agreement between the true Hurley stage and the
prediction from the models was only fair (Kappa ranged from 0.31 to 0.35). The prediction of
Table 5. Association between individual questions from the HS severity questionnaire and Hurley Stage of moderate versus mild, and severe versus mild.
Questions from the HS severity questionnaire Effect Hurley Stage Univariate a Multivariate b
Odd
Ratio
95% CI p-value Odd
Ratio
95% CI p-value
1: In the last 6 months, how many sore or painful boils/lumps at least 1 cm
(or half an inch) in diameter have you had? c
1 unit
increase
Moderate vs
Mild
1.03 (0.88 ,
1.21)
0.7108 1.03 (0.80 ,
1.32)
0.8464
Severe vs
Mild
1.05 (0.89 ,
1.25)
0.5379 0.87 (0.66 ,
1.14)
0.3072
2: In the last 6 months, what is the most pain you have experienced from
your boils or lumps (0 is no pain and 10 is unbearable pain)?
1 unit
increase
Moderate vs
Mild
0.89 (0.76 ,
1.05)
0.1618 0.84 (0.65 ,
1.08)
0.1680
Severe vs
Mild
0.98 (0.82 ,
1.17)
0.8132 0.86 (0.65 ,
1.13)
0.2714
3: Have you ever had boils or lumps heal leaving scars that feel harder than
the skin around the scars? (at any stage in your life, not just the last 6
months)
Yes vs No Moderate vs
Mild
1.66 (0.48 ,
5.75)
0.4218 1.10 (0.25 ,
4.84)
0.9035
Severe vs
Mild
2.33 (0.55 ,
9.83)
0.2483 2.87 (0.50 ,
16.54)
0.2371
4a: In the last 6 months, have the boils or scars restricted your movements? Yes vs No Moderate vs
Mild
0.60 (0.20 ,
1.84)
0.3719 0.46 (0.09 ,
2.38)
0.3557
Severe vs
Mild
1.88 (0.43 ,
8.17)
0.4005 1.17 (0.16 ,
8.38)
0.8722
4b: In the last 6 months, have the boils or scars interfered with your work/
school activities?
Yes vs No Moderate vs
Mild
1.30 (0.54 ,
3.16)
0.5566 2.44 (0.70 ,
8.48)
0.1602
Severe vs
Mild
3.48 (1.17 ,
10.32)
0.0247 5.76 (1.31 ,
25.32)
0.0205
4c: In the last 6 months, have the boils or scars caused you embarrassment or
shame?
Yes vs No Moderate vs
Mild
1.77 (0.60 ,
5.24)
0.2996 3.42 (0.81 ,
14.45)
0.0941
Severe vs
Mild
1.61 (0.52 ,
5.02)
0.4124 0.95 (0.19 ,
4.78)
0.9533
4d: In the last 6 months, have the boils or scars impacted on your personal or
physical relationships?
Yes vs No Moderate vs
Mild
0.56 (0.23 ,
1.39)
0.2130 0.32 (0.09 ,
1.18)
0.0868
Severe vs
Mild
1.44 (0.51 ,
4.10)
0.4899 0.84 (0.18 ,
4.00)
0.8264
5: Does the skin of the area affected ever heal completely (possibly leaving
scars)?
Yes vs No Moderate vs
Mild
0.81 (0.34 ,
1.93)
0.6343 0.83 (0.31 ,
2.26)
0.7159
Severe vs
Mild
0.42 (0.16 ,
1.09)
0.0735 0.42 (0.14 ,
1.26)
0.1212
6: Does the area affected by the scarring ever feel “lumpy” or the contour of
“bubble wrap”?
Yes vs No Moderate vs
Mild
2.13 (0.57 ,
7.94)
0.2590 3.04 (0.64 ,
14.44)
0.1629
Severe vs
Mild
1.31 (0.38 ,
4.58)
0.6707 1.32 (0.28 ,
6.21)
0.7235
7: How big is the area currently affected by scarring that you would regard as
ugly/distressing?
> 2 vs 2 Moderate vs
Mild
1.58 (0.65 ,
3.88)
0.3155 1.71 (0.53 ,
5.51)
0.3694
Severe vs
Mild
2.67 (1.04 ,
6.85)
0.0418 2.35 (0.66 ,
8.37)
0.1856
8: Does the area currently affected always contain some painful pus-filled
boils, lumps and scars?
Yes vs No Moderate vs
Mild
1.30 (0.47 ,
3.64)
0.6141 1.46 (0.42 ,
5.09)
0.5534
Severe vs
Mild
3.68 (0.92 ,
14.69)
0.0652 2.76 (0.53 ,
14.28)
0.2252
a Univariate results are from a multinomial logistic regression model with Hurley Stage as the outcome, and individual questions as the predictor variable.
b Multivariate results are from a multinomial logistic regression model with Hurley Stage as the outcome, and questions 1 to 8 as the predictor variables
c Due to small frequencies in some categories, question 1 was modelled as a continuous variable by mapping response 0 to 0, 1 to 1, 2–3 to 2.5, 4–6 to 5, and >6 to 8.
https://doi.org/10.1371/journal.pone.0200683.t005
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moderate/severe patients versus mild had reasonable SE (80% to 91%) and PPV (73% to 79%),
but poor SP (32% to 57%) and NPP (58% to 63%). The prediction of severe patients versus
mild/moderate had poor SE (27% to 55%) and PPV (45% to 64%) but reasonable SP (73% to
94%) and NPP (76% to 79%).
When analysing the ability of the HS severity questionnaire to predict Hurley Stage, results
from the three statistical models were consistent (Table 6). The ability of overall DLQI score to
predict Hurley Stage as also consistent with the questionnaire.
The overall DLQI scores showed only slight agreement with the Hurley Stage
(Kappa = 0.17) (Table 6). Using DLQI overall scores for the prediction of moderate/severe
patients versus mild had reasonable SE (78%) and PPV (72%) but poor SP (38%) and NPV
(47%). The prediction of severe patients versus mild/moderate had low SE (66%), PPV (40%),
and SP (57%) but a reasonable NPV (80%).
II. HS Epidemiology in Australia
A population-based cross-sectional study was performed to assess HS prevalence and diagno-
sis rate in the Australian adult population as well as demographics and management pathways
of individuals living with HS.
Study population. Out of the 17,050 Australian residents aged18 years old interviewed
by Roy Morgan Research, 11,433 agreed to answer the HS questionnaire. Gender distribution
of the non-respondent population was similar to that of the respondent population (p = 0.29).
Differences in terms of age and household distribution were statistically significant (p = 0.0061
and p<0.001 respectively) but not large (Table 7).
The characteristics of the respondent population (N = 11,433, Table 7) appeared generally
consistent with the Australian data reported by the Australian Bureau of Statistics [22], a stan-
dard reference source for Australian population demographics. A sensitivity analysis performed
after post-stratifying our sample to reflect the exact age and sex distribution of the Australian
population gave similar results. These results do not indicate a reason to suspect that our
respondent population is not representative as the Australian population.
Table 6. Predictive ability, sensitivity and specificity of the experimental self-administered HS severity questionnaire and DLQI against the Hurley Stage.
Hurley Categories a Model Agreement (κ) SE b SP b PPV b NPV b
Mild, Moderate, Severe Multinomial Logistic 0.35 n/a n/a n/a n/a
Canonical Discriminant Analysis 0.31 n/a n/a n/a n/a
DLQI Scores c 0.17 n/a n/a n/a n/a
Severe/Moderate versus Mild Multinomial Logistic n/a 0.80 0.57 0.79 0.58
Logistic Regression n/a 0.91 0.32 0.73 0.63
Canonical Discriminant Analysis n/a 0.82 0.54 0.78 0.59
DLQI Scores c n/a 0.78 0.38 0.72 0.47
Severe versus Mild/Moderate Multinomial Logistic n/a 0.48 0.80 0.50 0.79
Logistic Regression n/a 0.27 0.94 0.64 0.76
Canonical Discriminant Analysis n/a 0.55 0.73 0.45 0.79
DLQI Scores c n/a 0.66 0.57 0.40 0.80
a Hurley Stage I = Mild, Hurley Stage II = Moderate, Hurley Stage III = Severe
b Sensitivity (SE), Specificity (SP), Positive Predictive Value (PPV) and Negative Predictive Value (NPV)
c The overall DLQI score was used to predict Hurley Stage, where patients with a total DLQI score of 0–5 were predicted to be Hurley Stage I, 6–10 were predicted to be
Stage II, and 11–30 were predicted to be stage III.
https://doi.org/10.1371/journal.pone.0200683.t006
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HS prevalence in the Australian adult population. Based on the results from the HS
screening questionnaire, 88 out of the 11,433 respondents were identified as potentially having
HS (0.77%; 95% CI 0.62 to 0.95) (Table 8). Data by State are reported in Table 8 and a sensitiv-
ity analysis adjusted for stratification by state yielded the same point estimate and confidence
intervals.
Considering the previously reported sensitivity and positive predictive value of the screening
questionnaire [13], the prevalence of HS was estimated to be 0.67% (95% CI 0.53% to 0.84%)
(Table 9). HS appeared to be twice as prevalent in females compared to males (estimated HS
Table 7. Profilea of Non-participantsa versus participants.
Non-participants
(N = 5,617)a
Participants (N = 11,433)a p-value
Gender Male 2,808 (50.0%) 5,616 (49.1%) 0.29
Female 2,809 (50.0%) 5,817 (50.9%)
Age category 18–24 years 497 (8.8%) 1,042 (9.1%) 0.0061
25–34 years 880 (15.7%) 1,636 (14.3%)
35–49 years 1,233 (22.0%) 2,577 (22.5%)
50–64 years 1,343 (23.9%) 2,961 (25.9%)
65 years & over 1,664 (29.6%) 3,217 (28.1%)
Household location b VIC 1,401 (24.9%) 2,758 (24.1%) < .001
NSW/ACT 1,814 (32.3%) 3,894 (34.1%)
QLD 1,166 (20.8%) 2,230 (19.5%)
SA 503 (9.0%) 926 (8.1%)
WA 508 (9.0%) 1,262 (11.0%)
NT/TAS 225 (4.0%) 363 (3.2%)
a PARTICIPANTS: Approached Australian residents aged18yo who agreed to answer the HS questionnaire. NON-PARTICIPANTS: Individuals interviewed by Roy
Morgan Research who refused to answer the HS questionnaire.
b VIC = Victoria, NSW = New South Wales, ACT = Australian Capital Territory, QLD = Queensland, SA = South Australia, WA = Western Australia, NT = Northern
Territory and TAS = Tasmania.
https://doi.org/10.1371/journal.pone.0200683.t007
Table 8. Suspected HS cases by state and national total.
State a Total number of people interviewed b Individuals answering HS questions Suspected HS cases c
n % (95% CI)
VIC 4159 2758 26 0.94% (0.62%; 1.38%)
NSW / ACT 5708 3894 24 0.62% (0.40%; 0.92%)
QLD 3396 2230 14 0.63% (0.34%; 1.05%)
SA 1429 926 11 1.19% (0.59%; 2.12%)
WA 1770 1262 9 0.71% (0.33%; 1.35%)
NT 107 51 2 3.92% (0.48%; 13.46%)
TAS 481 312 2 0.64% (0.08%; 2.30%)
TOTAL 17050 11433 88 0.77% (0.62%; 0.95%)
a VIC = Victoria, NSW = New South Wales, ACT = Australian Capital Territory, QLD = Queensland, SA = South Australia, WA = Western Australia, NT = Northern
Territory and TAS = Tasmania.
b Australian residents participating in the Single Source establishment survey run by Roy Morgan Research.
c Based on the HS screening questionnaire (S1 Table).
https://doi.org/10.1371/journal.pone.0200683.t008
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prevalence after adjusting for SE and PPV of the screening question: 0.88% [95% CI 0.67–1.15]
in females vs 0.46% [95% CI 0.32–0.68] in males, p = 0.0068) (Table 9).
In women, boils were most commonly reported in the groin area (56.9%) and armpits
(44.8%), followed by under the breasts (25.9%), sexual organs (20.7%), anal region (19%), and
folds on the stomach/around the navel (17.2%) (Table 10). Men most commonly reported
boils in the groin area (43.3%) and anal region (36.7%), followed by armpits (30%), folds on
the stomach/around the navel (26.7%), sexual organs and under the breasts (both 6.7%)
(Table 10).
People living with HS in Australia: characteristics, diagnosis rate and management
pathways.
The diagnosis rate among the individuals who screened positive for HS was low, with only
6 out of the 88 individuals identified through the HS screening questionnaire having reported
a previous diagnosis of HS or acne inversa (6.8%; 95% CI 3.2% to 14.1%).
Among the individuals with a previous diagnosis of HS (N = 6), half (3/6) had been diag-
nosed by a dermatologist, 2/6 by a GP, 1/6 by an infectious disease specialist. A third (2/6) had
seen 5 or more clinicians regarding their condition before receiving a diagnosis. Among the
undiagnosed individuals suspected of having HS (N = 82), a quarter (21/82, 25.6%) had not
seen any clinicians regarding their boils, and the remainder had consulted General Practitioners
(59/61, 96.7%) and specialists, including dermatologists (12/61, 19.7%), surgeons (7/61, 11.5%)
and infectious disease specialists (5/61, 8.2%) as shown in Supporting information S5 Table.
A post-hoc analysis of demographic characteristics in suspected HS individuals (N = 88)
compared with non-HS individuals (N = 11,345) (Table 11) demonstrated a statistically
Table 9. Estimated prevalence of HS in Australia overall and by gender.
Overall
(N = 11433)
Females (N = 5817) Males
(N = 5616)
Chi-square
p-value c
Suspected HS cases a n/N (%)
[95% Cl]
88/11433 (0.77%) [0.62%; 0.95%] 58/5817 (1.0%) [0.77;1.29] 30/5616 (0.53%) [0.36;0.76] 0.0046
Estimated HS Prevalence b n/N (%)
[95% Cl]
77/11433 (0.67%)
[0.53; 0.84]
51/5817 (0.88%) [0.67; 1.15] 26/5616 (0.46%) [0.32; 0.68] 0.0068
a Based on the HS screening questionnaire. A suspected HS subject is a subject with a presence of outbreaks AND at least one boil location other than «Other
Locations».
b Based on Sensitivity and Positive Predictive Value of the HS screening questionnaire (Sensitivity 0.97, Positive Predictive Value 0.85) [13]
c Chi-square test to compare results in Females versus Males
https://doi.org/10.1371/journal.pone.0200683.t009
Table 10. Location of boils in suspected HS individuals, total and by gender.
Location of boils a Total
(N = 88)
Females
(N = 58)
Males
(N = 30)
Chi-square
p-value b
Groin 46/88 (52.3%) 33/58 (56.9%) 13/30 (43.3%) 0.2273
Armpits 35/88 (39.8%) 26/58 (44.8%) 9/30 (30.0%) 0.1779
Sexual organs 14/88 (15.9%) 12/58 (20.7%) 2/30 (6.7%) 0.0882
Anal region 22/88 (25.0%) 11/58 (19.0%) 11/30 (36.7%) 0.0691
Under the breasts 17/88 (19.3%) 15/58 (25.9%) 2/30 (6.7%) 0.0306
Folds on the stomach /
around the navel
18/88 (20.5%) 10/58 (17.2%) 8/30 (26.7%) 0.2988
a A subject can have reported more than one boil location.
b Chi-square test to compare results in Females versus Males
https://doi.org/10.1371/journal.pone.0200683.t010
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significant association between HS status and gender (p = 0.0046), age (p<0.0001), BMI
(p = 0.0307), smoking status (p<0.0001), employment status (p<0.0001) and income
Table 11. Characteristics of people living with HS in Australia compared to non-HS.
Not-HS
(N = 11345)
Suspected HSa
(N = 88)
Total
(N = 11433)
p-value
Gender Male 49.2% 34.1% 49.1% 0.0046
Female 50.8% 65.9% 50.9%
Age category 18–24 years 9.1% 6.8% 9.1% < .0001
25–34 years 14.3% 17.0% 14.3%
35–44 years 14.1% 33.0% 14.2%
45–54 years 16.6% 21.6% 16.7%
55–64 years 17.6% 14.8% 17.6%
65 years & over 28.3% 6.8% 28.1%
Country of Birth Australia 74.4% 86.4% 74.5% 0.0102
Other 25.6% 13.6% 25.5%
Household location VIC 24.1% 29.5% 24.1% 0.3508
NSW/ACT 34.1% 27.3% 34.1%
QLD 19.5% 15.9% 19.5%
SA 8.1% 12.5% 8.1%
WA 11.0% 10.2% 11.0%
NT/TAS 3.2% 4.5% 3.2%
Smoker No 83.9% 45.5% 83.6% < .0001
Yes 16.1% 54.5% 16.4%
Highest education level High-school 47.1% 48.9% 47.1% 0.7432
University 52.9% 51.1% 52.9%
Personal Annual Income Less than 20K (AUD) 27.4% 22.7% 27.3% 0.0321
20K-<40K (AUD) 27.4% 39.8% 27.5%
40K-<80K (AUD) 26.8% 27.3% 26.8%
80K(AUD) or more 18.5% 10.2% 18.4%
Employment status Employed 56.4% 45.5% 56.3% < .0001
Unemployed 8.2% 20.5% 8.3%
Retired 28.9% 17.0% 28.8%
Student 1.9% 2.3% 1.9%
Home duties 4.5% 14.8% 4.6%
Occupation Professional/Semi-pro/Sales 26.9% 27.5% 26.9% 0.2630
Executive/White collar 37.2% 50.0% 37.3%
Skilled/Semi-skilled 28.2% 22.5% 28.2%
Unskilled/Farm owner/worker 7.0% 0 7.0%
Unclassified 0.6% 0 0.6%
Marital status Married/De Facto 57.7% 52.3% 57.6% 0.1526
Single/Separated/Engaged/ Planning to marry 25.2% 34.1% 25.3%
Widowed/Divorced 17.1% 13.6% 17.1%
BMI category Underweight 1.4% 0 1.4% 0.0307
Acceptable weight 29.9% 17.2% 29.8%
Overweight 34.1% 20.7% 34.0%
Obese 32.3% 55.2% 32.5%
Unclassified 2.3% 6.9% 2.4%
a Individuals suspected of having HS (N = 88) based on the results of the HS screening questionnaire (S1 Table).
https://doi.org/10.1371/journal.pone.0200683.t011
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(p = 0.0321). Individuals suspected of having HS were more likely to be females, young, obese,
smokers, unemployed or at home duties and having a lower annual personal income in com-
parison with non-HS individuals (Table 11).
Clinical assessment of suspected HS cases. Of the 88 Roy Morgan Single Source Survey
participants identified as possibly having HS, 39 (44%) consented to share their contact details
to schedule a clinical assessment at the closest dermatology clinic, but only 12 of them actually
attended the visit at the dermatologist (Patients’ disposition is reported in the Supporting
information, S6 Table).
The demographic characteristics of the attendees (N = 12) and non-attendees (N = 76) are
shown in S7 Table. Some differences between these two groups could be observed in terms of
age, income, gender distribution, BMI and pain. Among those who attended the clinic, 50%
were men and 50% women (versus 32% men and 68% women in the non-attending group),
33% were 55 years old and over, and none of them were aged between 18-24yo (versus 20% 55
years old and 8% aged 18–24 years old in the non-attending group), 58% earned 40,000 AUD
or more (versus 33% in the non-attending group), 42% earned less than 40,000 AUD (versus
67% in the non-attending group), 29% were obese (versus 61% in the non-attending group),
17% had reported a pain of 8 or more out of 10 (versus 39.5% in the non-attending group),
and none of them reported a maximum pain of 10/10 (versus 16% in the non-attending
group)
Following the clinical assessment, 7 out of 12 individuals had a confirmed diagnosis of HS
(Table 12): 5 of them were Hurley Stage I and 2 Hurley Stage II. No Hurley Stage III cases were
identified at the dermatology clinic. Only one of these cases had been previously diagnosed
with HS, the remaining 6 cases were diagnosed for the first time during the clinical assessment,
despite 4 of them having previously consulted at least one health care professional regarding
their boils.
Table 12. Characteristics of the 7 confirmed cases of HS through physical examination among the 12 who attended the visit at the dermatologist.
Hurley Stage All
(N = 7)I
(N = 5)
II
(N = 2)
III
(N = 0)
Clinical diagnosis for HS 5/7 (71%) 2/7 (29%) 0 7/7 (100%)
Gender Male 1/5 (20%) 2/2 (100%) 0 3/7 (43%)
Female 4/5 (80%) 0 0 4/7 (57%)
HS/Acne Inversa previously diagnosed 1/5 (20%) 0 0 1/7 (14%)
Duration of HS symptoms Less than 12 months 0 0 0 0
12 months up to 5 years ago 0 1/2 (50%) 0 1/7 (14%)
5 years up to 10 years ago 2/5 (40%) 0 0 2/7 (29%)
10 years or longer 3/5 (60%) 1/2 (50%) 0 4/7 (57%)
Health Problems in addition to HS 3/5 (60.0%) 2/2 (100.0%) 0 5/7 (71.4%)
List of Health Problems in addition to HS a Obesity 2/5 (40.0%) 0 0 2/7 (28.6%)
Depression 2/5 (40.0%) 0 0 2/7 (28.6%)
Crohn’s disease 0 0 0 0
Ulcerative colitis 0 0 0 0
Spondyloarthropathy 0 0 0 0
Pyoderma Gangrenosum 0 0 0 0
Other 3/5 (60.0%) 2/2 (100.0%) 0 5/7 (71.4%)
a A subject can have answered more than one health problem in addition to HS. The denominator corresponds to the number of subjects who answered having a health
problem in addition to HS
https://doi.org/10.1371/journal.pone.0200683.t012
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Most of the individuals with a confirmed HS diagnosis had experienced symptoms of HS
for more than 5 years (6/7) and had concomitant health issues in addition to HS (5/7), includ-
ing obesity (2/5) and depression (2/5) (Table 12).
The 5/12 individuals who did not receive a confirmed diagnosis of HS at the clinic visit,
were diagnosed with: chronic folliculitis, epidermoid cyst affecting the back, psoriasis, recur-
rent furunculosis, ruptured acute folliculitis.
Of the 12 who attended the clinic visit, 10 had clinical photographs of their lesions taken.
The two missing sets of photographs belonged to two non-confirmed cases of HS. All the
lesions’ photographs were reviewed by an external reviewer with longstanding expertise in HS,
who was blinded to the results of the physical assessment performed by the clinicians. The
level of agreement was good (80%) (Table 13). The clinicians and expert reviewer agreed on 2
cases not corresponding to HS disease as well as on the 7 confirmed cases of HS (Table 13).
However, the external reviewer identified an additional case not diagnosed as HS in the clinic
as Hurley Stage I HS, bringing the number of confirmed HS cases to a total of 8 (Table 13).
The clinician and the expert reviewer agreed on the severity assessment of 6 out of 7 cases
(Table 13).
Discussion
I. Validation of an experimental self-administered questionnaire to predict
the severity of HS
A self-administered HS severity questionnaire (Table 1) was developed with the aim of provid-
ing a practical means of gauging HS severity distribution in a population-based epidemiology
study.
Overall, the experimental HS severity questionnaire and DLQI were found to be better than
chance at predicting Hurley Stage in HS patients, but not accurate enough to be an adequate
prediction tool. These results could at least partially be explained by the limitations of the Hur-
ley Staging system. Although considered to be the gold standard to assess grades of severity for
each area of the body affected by HS and being routinely used in clinical practice to define
appropriate treatment options, Hurley staging system cannot provide a global scoring of sever-
ity, doesn’t incorporate inflammatory and Quality of Life features and is based on static disease
characteristics which can be irreversible, such as scarring [5, 15]. Of note, many study patients
had received or were currently receiving treatment for HS, but improvement of their disease
might have not been reflected in their current Hurley stage because of the static nature of this
severity measure. Acknowledging the limitations of the Hurley Staging, efforts from groups of
HS experts are underway to define a more detailed and suitable subclassification of the disease
[23, 24]. Future studies could address the ability of the HS severity questionnaire, or part of it,
to predict severity as defined by new severity classification methods.
Table 13. Agreement between clinical and expert assessments in suspected HS individuals attending the dermatology visit (N = 12).
Expert Severity Diagnosis
Missing Diagnosed as not HS Stage I Stage II Stage III
Clinical Severity Diagnosis
Missing Photographs 2 0 0 0 0
Diagnosed as not HS 0 2 1 0 0
Stage I 0 0 5 0 0
Stage II 0 0 1 1 0
Stage III 0 0 0 0 0
https://doi.org/10.1371/journal.pone.0200683.t013
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DLQI is a 10-item survey evaluating the quality of life in patients with a skin disease, cover-
ing six domains: symptoms and feelings, daily activities, leisure, work and school, personal
relationships and treatment [25]. While reduction in severity scores in dermatologic condi-
tions, such as psoriasis, can correlate well with DLQI [26], it can be difficult to correlate abso-
lute values of disease severity and DLQI given the subjectivity of the latter. In addition to the
limitations of the Hurley staging discussed above, this could have also contributed to the
observed lack of ability of DLQI to predict Hurley Stage in our cross-sectional study.
Among the 8 questions included in the experimental HS severity questionnaire (Table 1),
interference of the boils or scars with work/school activities and the area of ugly/distressing
scarred skin in HS patients were associated with Hurley stage in the univariate analyses. How-
ever, the association with the area of scarred skin was not statistically significant in the multi-
variate analyses. These data could be leveraged for the future development of self-administered
tools to assess HS severity.
Despite the HS severity questionnaire and DLQI lacking the ability to accurately predict
Hurley Stage in HS patients, our data provided insights into the burden of the disease. The
overall DLQI scores reported in our study demonstrated that HS had a large or extremely large
effect on quality of life for nearly 50% of the study patients with a mean DLQI score of 11.8
±8.1 in the overall study population. Study patients were also suffering from considerable pain,
with approximately half of them rating their maximum pain as 8 out of 10 or higher in the last
6 months. These data are not surprising given the nature, localization and chronicity of HS
lesions and are in agreement with the body of literature reporting that the impact of HS on
quality of life is higher than in many other debilitating diseases (with a DLQI ranging from a
mean of 8.4 to 20) [27, 28] and correlates with pain [29].
Interestingly, patients with more severe disease appeared to have had HS symptoms for a
longer period of time. This is consistent with a progressive nature of the disease as suggested
by previous reports showing that over time, the inflammatory lesions affect more areas of the
body and grow in both size and number [17, 30, 31].
II. HS Epidemiology in Australia
Based on face-to-face household interviews of a large (N = 11,433) representative sample of the
adult Australian population using a previously validated HS screening questionnaire (S1
Table) [13], the prevalence of HS in Australia was estimated to be 0.67% (95% CI 0.53%-
0.84%) after adjusting for the previously reported sensitivity and positive predictive value of
the screening questionnaire [13].
Several studies have previously attempted to determine HS prevalence in different settings
and using different methods. The result is a set of highly variable estimations of HS prevalence,
ranging between 0.03% and 4% of the population, with the majority of the studies being small
and/or from selected populations [6]. However, prevalence estimates coming from cross-sec-
tional, population-based studies using screening questions and/or clinical assessment, like our
study, are usually considered to be the most reliable. To our knowledge, only 3 studies have so
far investigated HS prevalence in a population-based sample [32–34], and only 1 of them used
a validated screening questionnaire [32], while the others used a questionnaire that had not
been validated [33, 34]. With the former study, Vinding and colleagues [32] found a prevalence
of 2.1% (95% CI 1.88–2.32) in the Danish population aged 30 years old and over. Data were
obtained from the Danish General Suburban Population Study (GESUS), a general cross-sec-
tional population study of the health status of the population in Naestved Municipality. The
following factors could at least partially explain the different prevalence rates observed in this
study and the Danish one: (I) it is unknown how much Naestved Municipality is representative
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of the entire Danish population, while the sample used in our study was representative of the
Australian population including rural and urban areas; (II) participants were invited to partici-
pate to the GESUS health study by mail, the participation rate was therefore relatively low
(49%) and a large number of participants (769 out of a total of 17,454) were excluded due to
missing data. These factors may have introduced a bias to the results. The response rate in our
study was 67% and the demographic characteristics of the respondent population were similar
to that of non-respondents and appeared generally consistent with the Australian general pop-
ulation data; (III) No data for adults aged less than 30 years old were included in the Danish
study; (IV) As opposed to the approach described herein, the prevalence rate reported in the
Danish study was not adjusted based on the SE and PPV of the HS screening questionnaire
used; (V) prevalence estimates could fluctuate based on geography and ethnicity [35, 36]. In
line with our findings, a recent study using a very large number of UK residents with research-
standard medical records from a large database found a 0.77% HS prevalence[11].
HS in Australia appeared to be twice as prevalent in females compared to males, in agree-
ment with previous studies reporting female:male ratios ranging from 2:1 to 5:1 [6, 35, 37].
Overall, boils were mainly reported in the groin and armpits, in agreement with the data
reported from a recent Italian study [38], and there appeared to be a trend towards slightly dif-
ferent patterns in the location of boils between women and men, as previously suggested by
other research groups [15, 18, 39, 40]. In our study, males reported the anal region to be the
second most common location of boils, while in females the second most common location of
boils was reported to be armpits. Not unexpectedly, boils under the breasts were significantly
more prevalent in women compared to males.
Interestingly, the diagnosis rate amongst the suspected HS cases was low, with only 6.8%
(95% CI 3.2% -14.1%) having reported previously receiving a diagnosis of HS/acne inversa. An
average of 7.2 years between symptom onset and HS diagnosis and high frequency of undiag-
nosed and misdiagnosed cases have previously been reported [7, 35]. Out of the 7 HS cases
confirmed at the dermatology clinic, 6 had had HS symptoms for more than 5 years. Delayed
diagnosis is a significant problem in the management of HS, as it is likely to result in under-
treatment and, as a consequence, disease progression and increased disability. In our study,
most of the confirmed cases of HS (4/7) were not receiving any treatment for their condition.
Given that a quarter of the undiagnosed individuals suspected of having HS had not seen any
clinician regarding their boils and that many diagnosed and undiagnosed individuals had seen
several clinicians/specialists regarding their condition, it can be speculated that the low diag-
nosis rate observed in the Australian general population may result from a combination of
decentralization of care, lack of familiarity of some clinicians with the disease, and many
patients not seeking medical help for single or infrequently recurring boils. This would indi-
cate a need to increase awareness of the disease in Australia among both the broader medical
community and the general population.
Here we showed that individuals living with HS identified through the screening question-
naire were more likely to be females, young, obese, smokers, unemployed or at home duties and
having a lower annual personal income in comparison with non-HS individuals. Smoking and
obesity are known risk factors for HS [28, 35, 41] and the mean age of HS onset is in the early
20s with a decline of prevalence after the age of 55 [35]. Although cross-sectional studies do not
provide data to establish causality, it may be speculated that the patients’ disease-related disabili-
ties may affect their ability to work and subsequently also have a socioeconomic impact.
Only 12 out of the 88 suspected HS individuals attended the visit at the dermatologist, with
10 of them having photographs of their lesions taken. 7/12 received a confirmed diagnosis of
HS through physical assessment. An additional individual was diagnosed with HS through the
review of photographs by a blinded independent HS expert, bringing the number of confirmed
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HS cases to 8/12 (67%). Most of the HS patients had Stage I disease, while none were identified
with Stage III disease. Obesity and depression, which are known comorbid conditions in HS
[28, 35], were noted even in this small number of cases.
The main limitation of this study was the small proportion of patients attending the clinical
assessment, which can not be considered representative of the overall 88 individuals suspected
of having HS. The challenges in travel time characteristic of Australia’s dispersed population
may have contributed to the low attendance rate. Also, although the number of individuals
attending the clinics was too small to draw any definitive conclusions, characteristics of the
attendees compared to those who did not attend the clinic suggest that there might have been
a self-selection bias enriching the attending population with false negatives, given that the
characteristics of that group appeared to be dissimilar to the typical HS patient profile, in con-
trast to the characteristics observed in the group who did not attend the clinic. It could be spec-
ulated that individuals affected by HS could have had more difficulty traveling to the clinic.
This speculation is supported by the fact no Hurley Stage III HS cases (who are more likely to
be limited by the disease-related physical and psychological disabilities) were identified at the
clinical assessment. The possible self-selection bias of people attending the clinical assessment
further supports the benefit of using a validated screening questionnaire on a representative
sample of the general population, as in our study, as opposed to using data from medical data-
bases or patients under medical care.
The low and unrepresentative attendance to the clinical assessment does not affect the
validity of the epidemiology data obtained through the population-based survey as the HS
screening questionnaire had already been previously validated by Esmann and colleagues [13],
however we were not able to provide a further confirmation of the sensitivity of the
questionnaire.
Because the data obtained from the clinical examination can not be generalized and the
experimental self-administered severity questionnaire did not predict Hurley Stage, it was not
possible to report proportion of mild, moderate and severe disease in the Australian HS
population.
To our knowledge, our study represents one of the most rigorous and largest general popu-
lation-based HS epidemiological studies reported thus far, and for the first time sheds light on
the prevalence and impact of HS in Australia as well as the demographic characteristics of the
sufferers. It can be speculated that the diverse genetic background of the Australian population
may support the generalizability of our findings to a broader global population.
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